Search

Your search keyword '"Melanis, Konstantinos"' showing total 15 results
Start Over Author "Melanis, Konstantinos"
15 results on '"Melanis, Konstantinos"'

1. Symptomatic Unilateral Carotid Artery Disease

Author

Melanis, Konstantinos, primary, Athanasaki, Athanasia, additional, Bakola, Eleni, additional, Chondrogianni, Maria, additional, Lazaris, Andreas, additional, Akrivaki, Alexandra, additional, Triantafyllou, Alexandros Stavros, additional, Kotsali-Peteinelli, Vasiliki, additional, Bonakis, Anastasios, additional, Paraskevas, George P., additional, and Tsivgoulis, Georgios, additional

Published
2024
Full Text
View/download PDF

4. Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience

Author

Melanis, Konstantinos, primary, Stefanou, Maria-Ioanna, additional, Kitsos, Dimitrios K., additional, Athanasaki, Athanasia, additional, Theodorou, Aikaterini, additional, Koropouli, Eleftheria, additional, Keramida, Anna, additional, Dimitriadou, Evangelia Makrina, additional, Tzanetakos, Dimitrios, additional, Andreadou, Elizabeth, additional, Koutroulou, Ioanna, additional, Giannopoulos, Sotirios, additional, Paraskevas, George P., additional, Tsivgoulis, Georgios, additional, and Tzartos, John S., additional

Published
2024
Full Text
View/download PDF

5. Clinical Characteristics, Neuroimaging Markers, and Outcomes in Patients with Cerebral Amyloid Angiopathy: A Prospective Cohort Study

Author

Theodorou, Aikaterini, primary, Palaiodimou, Lina, additional, Papagiannopoulou, Georgia, additional, Kargiotis, Odysseas, additional, Psychogios, Klearchos, additional, Safouris, Apostolos, additional, Bakola, Eleni, additional, Chondrogianni, Maria, additional, Kotsali-Peteinelli, Vasiliki, additional, Melanis, Konstantinos, additional, Tsibonakis, Athanasios, additional, Andreadou, Elissavet, additional, Vasilopoulou, Sofia, additional, Lachanis, Stefanos, additional, Velonakis, Georgios, additional, Tzavellas, Elias, additional, Tzartos, John S., additional, Voumvourakis, Konstantinos, additional, Paraskevas, Georgios P., additional, and Tsivgoulis, Georgios, additional

Published
2023
Full Text
View/download PDF

11. Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy

Author

Stefanou, Maria Ioanna Karachaliou, Eleni Chondrogianni, Maria Moschovos, Christos Bakola, Eleni Foska, Aikaterini Melanis, Konstantinos Andreadou, Elisabeth Voumvourakis, Konstantinos Papathanasiou, Matilda Boutati, Eleni Tsivgoulis, Georgios

Subjects
viruses
Abstract

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.

Published
2022

12. Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease: Review and Meta-Analysis

Author

Athanasaki, Athanasia, primary, Melanis, Konstantinos, additional, Tsantzali, Ioanna, additional, Stefanou, Maria Ioanna, additional, Ntymenou, Sofia, additional, Paraskevas, Sotirios G., additional, Kalamatianos, Theodosis, additional, Boutati, Eleni, additional, Lambadiari, Vaia, additional, Voumvourakis, Konstantinos I., additional, Stranjalis, George, additional, Giannopoulos, Sotirios, additional, Tsivgoulis, Georgios, additional, and Paraskevas, George P., additional

Published
2022
Full Text
View/download PDF

15. Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis.

Author

Theodorou A, Melanis K, Bakola E, Chondrogianni M, Kiamili A, Plomaritis P, Psychogios K, Safouris A, Kargiotis O, Ntais E, Stefanou MI, Palaiodimou L, Sarraj A, Seiffge DJ, Giannopoulos S, and Tsivgoulis G

Subjects
Humans, Aged, Male, Female, Intracranial Hemorrhages chemically induced, Intracranial Hemorrhages drug therapy, Treatment Outcome, Dabigatran therapeutic use, Dabigatran adverse effects, Registries, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antithrombins therapeutic use, Antithrombins adverse effects, Thrombolytic Therapy methods, Ischemic Stroke drug therapy
Abstract

Background and Objectives: Limited data exist on the safety of IV thrombolysis (IVT) for acute ischemic stroke (AIS) after dabigatran reversal with idarucizumab. We sought to evaluate the safety and efficacy of idarucizumab pretreatment in patients with AIS receiving IVT., Methods: A national registry-based study evaluated the safety and efficacy of IVT in this specific subgroup. We also conducted a systematic review and meta-analysis of cohort studies and case series, aiming to document the pooled rates of (1) symptomatic intracranial hemorrhage (sICH), (2) any intracranial hemorrhage, (3) 3-month mortality, and (4) the proportion of excellent (modified Rankin Scale [mRS] scores 0-1) and (5) good (mRS scores 0-2) functional outcome at 3 months among patients with AIS, who received IVT after dabigatran reversal with idarucizumab. Moreover, we sought to compare these outcomes between IVT-treated patients after dabigatran reversal with idarucizumab and IVT-treated patients without dabigatran pretreatment., Results: Thirteen cohorts including our nation-wide registry-based cohort and 1 case series comprising 553 patients with AIS (mean age: 75 years; male sex: 65%; median baseline NIH Stroke Scale score: 11 points) receiving idarucizumab before IVT were included in this meta-analysis. The pooled rate of sICH after IVT after idarucizumab administration was 4% (95% CI 1-9; I 2 = 26%), while the pooled rates of any intracranial hemorrhage and 3-month mortality were 10% (95% CI 5-16; I 2 = 24%) and 18% (95% CI 10-27; I 2 = 0%), respectively. The pooled rates of excellent and good functional outcomes at 3 months were 56% (95% CI 27-83; I 2 = 69%) and 70% (95% CI 57-81; I 2 = 40%), respectively. The risk of sICH (risk ratio [RR] 1.86; 95% CI 0.91-3.80; I 2 = 0%), any intracranial hemorrhage (RR 1.76; 95% CI 0.99-3.11; I 2 = 8%), and 3-month mortality (RR 1.50; 95% CI 0.91-2.48; I 2 = 0%) did not differ between patients with AIS receiving IVT with and without idarucizumab. Moreover, idarucizumab administration was associated with higher likelihood of achieving a 3-month good functional outcome (RR 1.35; 95% CI 1.11-1.65; I 2 = 27%)., Discussion: IVT for AIS after dabigatran reversal with idarucizumab seems to be safe and effective in observational studies with limited number of patients. Randomized-controlled clinical trials are warranted to provide robust evidence on the safety and efficacy of IVT in this specific AIS subgroup.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results